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aspase-independent death mechanisms have been
shown to execute apoptosis in many types of neuronal
injury. P53 has been identiﬁed as a key regulator of
neuronal cell death after acute injury such as DNA damage,
ischemia, and excitotoxicity. Here, we demonstrate that
p53 can induce neuronal cell death via a caspase-mediated
process activated by apoptotic activating factor-1 (Apaf1)
and via a delayed onset caspase-independent mechanism.
In contrast to wild-type cells, Apaf1-deﬁcient neurons exhibit
delayed DNA fragmentation and only peripheral chromatin
condensation. More importantly, we demonstrate that
apoptosis-inducing factor (AIF) is an important factor involved
in the regulation of this caspase-independent neuronal cell
C
 
death. Immunoﬂuorescence studies demonstrate that AIF is
released from the mitochondria by a mechanism distinct from
that of cytochrome-c in neurons undergoing p53-mediated
cell death. The Bcl-2 family regulates this release of AIF
and subsequent caspase-independent cell death. In addition,
we show that enforced expression of AIF can induce
neuronal cell death in a Bax- and caspase-independent
manner. Microinjection of neutralizing antibodies against
AIF signiﬁcantly decreased injury-induced neuronal cell
death in Apaf1-deﬁcient neurons, indicating its importance
in caspase-independent apoptosis. Taken together, our
results suggest that AIF may be an important therapeutic
target for the treatment of neuronal injury.
 
Introduction
 
Apoptotic cell death plays an important role in brain devel-
opment as well as in neuronal injury and disease. In the
developing nervous system, apoptosis is required for the
establishment of appropriate cell numbers and for the elimi-
nation of improperly connected neurons (Pettmann and
Henderson, 1998). In the adult nervous system, the inap-
propriate induction of apoptotic cell death contributes to
the neuropathology associated with a number of neurode-
generative diseases (Portera-Cailliau et al., 1995; Smale et
al., 1995) as well as acute neurological insults (Nitatori et
al., 1995; Yakovlev et al., 1997). Therefore, identifying the
molecular mechanisms that regulate neuronal apoptosis is
essential for the development of therapeutic strategies for the
treatment of such neurological conditions.
A number of death regulatory molecules have been impli-
cated in neuronal injury induced by ischemia, including
p53, PARP, c-jun, and plasma membrane death receptor
ligand systems (Eliasson et al., 1997; Endres et al., 1997;
Herdegen et al., 1998; Morrison and Kinoshita, 2000; Martin-
Villalba et al., 2001). Importantly, several lines of evidence
suggest that p53 is a key upstream initiator of the cell death
process after neuronal injury. P53 expression has been re-
ported to be upregulated in response to excitotoxins, hy-
poxia, and ischemia (Xiang et al., 1996; Banasiak and Had-
dad, 1998; McGahan et al., 1998). Accordingly, we and
others have shown that enforced expression of p53 alone is
sufficient to trigger apoptosis in postmitotic neurons (Slack
et al., 1996; Xiang et al., 1998; Cregan et al., 1999). In addi-
tion, it has been demonstrated that brain damage induced
by ischemia or kainic acid excitotoxicity is significantly re-
duced in mice carrying a null mutation for the p53 gene
(Crumrine et al., 1994; Morrison et al., 1996). Further-
more, cultured neurons derived from p53-deficient mice
have been shown to be resistant to excitotoxins (Xiang et al.,
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1996, 1998), DNA damaging agents (Johnson et al., 1998;
Xiang et al., 1998; Morris et al., 2001), and hypoxia (Hal-
terman et al., 1999).
Caspases are a family of cysteine proteases that have been
implicated as key effector molecules in the execution of ap-
optotic cell death (Cryns and Yuan, 1998). Recent studies
have demonstrated the involvement of caspases in the execu-
tion of neuronal cell death both during development and af-
ter injury. Mouse embryos deficient for apoptotic activating
factor-1 (Apaf1),* caspase-9, or caspase-3 display severe
craniofacial malformations and dramatically enhanced neu-
ronal cell numbers (Kuida et al., 1996, 1998; Cecconi et al.,
1998). These gross developmental defects were attributed to
failed apoptosis in the neuroepithelium. The importance of
the caspase signaling cascade has also been demonstrated in
many models of neuronal injury, including traumatic brain
injury and ischemia (Hara et al., 1997; Yakovlev et al., 1997;
Cheng et al., 1998).
Although caspases have been recognized as important me-
diators of apoptosis, there is accumulating evidence indicat-
ing the existence of caspase-independent mechanisms of
neuronal cell death (Rideout and Stefanis, 2001). For exam-
ple, several groups have indicated that in excitotoxic cell
death, caspases are not activated and peptide-based caspase
inhibitors do not invoke neuroprotection (Johnson et al.,
1999; Lankiewicz et al., 2000). Similarly, in experimental
models of stroke, caspase inhibition affords protection in
certain neuronal populations, but not in others (Rideout
and Stefanis, 2001; Zhan et al., 2001). Furthermore, in a
number of neuronal cell death paradigms in which caspases
are normally activated, inhibition of caspase activity delays,
but does not prevent cell death from occurring (Miller et al.,
1997; Stefanis et al., 1999; D’Mello et al., 2000; Keramaris
et al., 2000; Selznick et al., 2000). Thus it appears that, at
least in certain neuronal death paradigms, caspase inhibition
simply results in the activation or recruitment of compensa-
tory cell death processes. Although there has been extensive
investigation on caspase-mediated cell death processes,
much less is known about the molecular mechanisms in-
volved in the regulation of caspase-independent cell death.
Apoptosis-inducing factor (AIF) is a putative caspase-
independent effector of cell death that has recently been
cloned and characterized (Susin et al., 1999). AIF is a mito-
chondrial intermembrane flavoprotein that has been re-
ported to be released from the mitochondria and to translo-
cate to the nucleus in response to specific death signals
(Daugas et al., 2000). Furthermore, this apoptotic factor has
been shown to cause high molecular weight DNA fragmen-
tation and chromatin condensation in cells and isolated nu-
clei in a caspase-independent manner (Susin et al., 1999,
2000; Daugas et al., 2000).
In the present study, we demonstrate that p53 can induce
neuronal cell death via a caspase-mediated process in the
presence of Apaf1 and via a delayed onset caspase-indepen-
dent mechanism in the absence of Apaf1. More importantly,
we demonstrate that AIF is an important factor involved in
the regulation of caspase-independent cell death induced by
p53-mediated neuronal injury.
 
Results
 
P53 can induce neuronal cell death via 
Apaf1-dependent and -independent pathways
 
We have previously reported that caspase-3–deficient neu-
rons exhibit a significant delay in p53-induced cell death
(Cregan et al., 1999; Keramaris et al., 2000). Nevertheless,
Figure 1. Camptothecin induces 
neuronal cell death via a caspase-
mediated process in the presence of 
Apaf1 and via a delayed onset caspase-
independent pathway in the absence 
of Apaf1. Wild-type and Apaf1-deficient 
cortical neurons were treated with 
camptothecin (10  M) in the presence 
or absence of a broad spectrum caspase 
inhibitor (BAF, 50  M). (A) Neuronal 
survival was measured by live/dead assay 
(n   4). (B) Caspase-3 activity was deter-
mined by DEVD-AFC cleavage (n   3). 
(C) The proportion of apoptotic cells was 
determined by TUNEL staining (n   3). 
(D) Nuclear morphology was assessed 
by Hoechst staining. Bar, 15  m.
 
*Abbreviations used in this paper: AIF, apoptosis-inducing factor; Apaf1,
apoptotic activating factor-1; BAF, Boc-aspartyl (OMe)-fluoromethylketone;
MOI, multiplicity of infection. 
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in the absence of caspase-3, neurons do eventually undergo
apoptosis, suggesting that either additional caspases or cas-
pase-independent effectors could also be involved. To distin-
guish between these possibilities, we examined p53-induced
cell death in the presence or absence of Apaf1, a critical co-
factor of the mitochondrial-initiated caspase activation com-
plex. Indeed we have recently demonstrated that p53-induced
neuronal cell death involves the transcriptional upregulation
of Apaf1 (Fortin et al., 2001).
In the present study, we examined long-term survival in
Apaf1-deficient neurons to determine whether caspase-inde-
pendent cell death occurred. We treated wild-type or Apaf1-
deficient neurons with the DNA damaging agent campto-
thecin, which has previously been shown to induce neuronal
cell death through a p53-dependent mechanism (Xiang et
al., 1998; Morris et al., 2001). Camptothecin treatments
were administered in the presence or absence of a broad
spectrum caspase inhibitor, Boc-aspartyl (OMe)-fluoro-
methylketone (BAF), to account for the possible involve-
ment of Apaf1-independent pathways of caspase activation.
In wild-type neurons, treatment with camptothecin resulted
in a rapid loss of neuronal survival beginning at 
 
 
 
12 h, and
within 24 h, survival had decreased to 
 
 
 
20% (Fig. 1 A). In
contrast, Apaf1-deficient neurons remained largely viable
during the first 24 h of treatment. However, after 24 h, cell
survival began to decline and by 48 h, 
 
 
 
30% of Apaf1
 
 
 
/
 
 
 
neurons remained viable. These results demonstrate that p53
induces neuronal cell death through a rapid Apaf1-dependent
pathway in wild-type neurons, and through a delayed path-
way in Apaf1-deficient neurons.
These two cell death pathways could be further distin-
guished on the basis of caspase involvement and cellular
morphology. In wild-type neurons, camptothecin-induced
cell death was associated with an approximate ninefold in-
crease in caspase-3 activity at 16 h (Fig. 1 B), and this was
accompanied by a significant increase in the fraction of cells
exhibiting DNA fragmentation, as detected by TUNEL as-
say (50.2 vs. 12.3% in controls; Fig. 1 C). Consistent with a
requirement for caspases in this death process, the pan-cas-
pase inhibitor BAF significantly reduced the fraction of
TUNEL-positive cells at 16 h (11.8 vs. 50.2%; Fig. 1 B),
and significantly enhanced neuronal survival at 24 h (70.7
vs. 19.8%; Fig. 1 A). In contrast, the delayed cell death in-
duced by camptothecin in Apaf1-deficient neurons was not
associated with caspase-3 activation (Fig. 1 B), and the loss
of neuronal survival was not prevented by BAF (Fig. 1 A).
This indicated that cell death induced in Apaf1
 
 
 
/
 
 
 
 neurons
did not involve additional or compensatory caspase activa-
tion pathways. Interestingly, the delayed cell death observed
in Apaf1
 
 
 
/
 
 
 
 neurons was associated with an increase in
TUNEL-positive cells, however, this only became evident at
much later times (42.2 vs. 8.5% in controls at 48 h; Fig. 1
C). Furthermore, this TUNEL labeling was not accompa-
nied by caspase-3 activation (Fig. 1 B) and was not pre-
vented by BAF (Fig. 1 C), indicating that, unlike in wild-
type neurons, this DNA fragmentation was not caspase
mediated. Cell death in wild-type and Apaf1
 
 
 
/
 
 
 
 neurons
could be further distinguished on the basis of nuclear mor-
phology. Neurons undergoing Apaf1-mediated cell death
displayed typical apoptotic features, including dense chro-
matin condensation, nuclear pyknosis, and in some cases
nuclear fragmentation (Fig. 1 D, arrow). Apaf1-deficient
neurons, in contrast, exhibited partial nuclear pyknosis and
margination but not complete chromatin condensation (Fig.
1 D, arrowhead).
Next, to determine whether p53 could directly induce cas-
pase-independent cell death in the absence of Apaf1, we in-
fected Apaf1
 
 
 
/
 
 
 
 and Apaf1
 
 
 
/
 
 
 
 cortical neurons with a re-
combinant adenoviral vector carrying an expression cassette
for either p53 or the control gene LacZ. Adenoviral-medi-
ated expression of p53 resulted in a significant induction of
TUNEL-positive cell death in both wild-type (61.4 vs.
16.8%) and Apaf1-deficient neurons (44.5 vs. 14.9%) rela-
tive to Ad-LacZ–infected controls (Fig. 2 A). Cell death in-
duced by direct p53 expression was associated with a signifi-
cant induction of caspase-3 activity in wild-type neurons
(4.7-fold increase), but not in Apaf1-deficient neurons (Fig.
2 B). Furthermore, Ad-p53–induced TUNEL labeling was
not prevented in the presence of a pan-caspase inhibitor (un-
published data). This indicated that, similar to the delayed
cell death induced by camptothecin, DNA fragmentation
triggered by direct p53 expression in Apaf1-deficient neu-
rons was induced in a caspase-independent manner. Fur-
thermore, whereas wild-type neurons undergoing cell death
exhibited classical apoptotic nuclear morphology, Apaf1-
deficient neurons again displayed only peripheral chromatin
condensation and intermediate pyknosis (unpublished data).
These results indicate that the p53 pathway can trigger a cas-
pase-mediated cell death process in the presence of Apaf1
and a slower caspase-independent death process in the ab-
sence of Apaf1.
Figure 2. Direct expression of p53 induces neuronal cell death 
via a caspase-mediated process in the presence of Apaf1 and via a 
caspase-independent pathway in the absence of Apaf1. Wild-type 
and Apaf1-deficient neurons were infected with Ad-p53 or the 
control vector Ad-LacZ at 50 multiplicity of infection (MOI). (A) The 
fraction of TUNEL-positive cells was measured 72 h after infection 
(n   3). (B) Caspase-3 activity was measured at 72 h by DEVD-AFC 
cleavage (n   3). 
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P53 triggers mitochondrial release of AIF
 
It has previously been shown that in neurons, camptothecin
triggers the release of cytochrome-c from the mitochondria
(Stefanis et al., 1999). Upon release into the cytoplasm, cy-
tochrome-c is believed to interact with Apaf1 and facilitate
the formation of a caspase activating complex with caspase-9
(Li et al., 1997; Hu et al., 1999). AIF is a mitochondrial in-
termembrane protein that, like cytochrome-c, has been re-
ported to be released from the mitochondria in response to
specific death stimuli (Daugas et al., 2000). In contrast to
cytochrome-c, however, AIF has been reported to induce ap-
optotic nuclear morphology independent of caspase activity
(Susin et al., 2000). Therefore, in the present study, we in-
vestigated a potential role of AIF in the Apaf1/caspase-inde-
pendent pathway of p53-induced neuronal cell death.
To determine whether AIF was released from the mito-
chondria during p53-mediated neuronal injury, we exam-
ined the cellular localization of AIF by immunofluores-
cence in neurons infected with Ad-p53 or Ad-LacZ. Our
results demonstrate that the majority of neurons infected
with the control vector displayed a punctate, cytoplasmic
staining pattern that colocalized with a mitochondrial-spe-
cific marker (Fig. 3 A). In contrast, AIF staining was dra-
matically diminished and did not colocalize with the mito-
chondrial marker in Ad-p53–infected neurons exhibiting
morphological features of apoptotic cell death (Fig. 3 A,
arrow). Despite the significant decrease in immunostaining
intensity, Western blot analysis demonstrated that the dy-
ing cells retained AIF and cytochrome-c (Fig. 3 B), sug-
gesting that these proteins may diffuse from the cells
during the fixation and permeabilization procedure. Fur-
thermore, many Apaf1-deficient neurons infected with Ad-
p53 exhibited diffuse AIF staining in the nucleus (Fig. 3 A,
arrowhead). These results suggest that AIF is released from
the mitochondria and can translocate to the nucleus during
p53-induced neuronal cell death. It is unclear why AIF
fails to translocate to the nucleus in Apaf1
 
 
 
/
 
 
 
 neurons;
however, it is possible that the early activation of caspases
in wild-type cells results in the inactivation of the process
responsible for AIF nuclear translocation.
Figure 3. AIF is released from the mitochondria during p53-induced 
neuronal cell death. (A) Apaf1
 /  and Apaf1
 /  cortical neurons 
were infected at 50 MOI with Ad-p53 or the control vector 
Ad-LacZ. After 72 h, neurons were labeled with a mitochondrial-
specific dye (mitotracker green FM, 0.5  M), fixed, and immunostained 
for AIF. The incorporation of mitotracker green FM into mitochondria does not depend on the mitochondrial transmembrane potential. 
Neurons undergoing p53-mediated cell death exhibit loss of mitochondrial AIF staining (arrows) and nuclear translocation (arrowheads). Bar, 
25  m. (B) Western blot analysis of AIF and cytochrome-c levels in neurons 48 h after infection with Ad-p53 or Ad-LacZ. (C) P53
 / , Apaf1
 / , 
and corresponding wild-type neurons were treated with camptothecin (10  M) and then fixed and stained for AIF after 24 h. Representative 
images were captured and the proportion of cells exhibiting punctate, mitochondrial AIF staining was scored (n   3).
Figure 4. AIF and cytochrome-c are released by distinct mechanisms during camptothecin-induced neuronal cell death. (A) Apaf1-deficient 
neurons were treated with camptothecin (10  M) and at the indicated times, cells were labeled with CMX-Ros to assess mitochondrial 
transmembrane potential, or fixed and immunostained for AIF or cytochrome-c. Images were captured and the fraction of cells retaining 
mitochondrial transmembrane potential or exhibiting mitochondrial cytochrome-c/AIF staining was scored (n   4). (B) Photomicrographs 
of Apaf1
 /  neurons treated with camptothecin for 12 h and stained for AIF, cytochrome-c, or CMX-Ros and the corresponding Hoechst or 
phase images. Bar, 30  m. 
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To ascertain whether AIF is released from the mitochon-
dria in response to endogenous p53 activation, we examined
AIF immunoreactivity after camptothecin treatment in neu-
rons derived from p53- or Apaf1-deficient mice and corre-
sponding wild-type littermates. Camptothecin treatment re-
sulted in a significant decrease in the fraction of cells
retaining mitochondrial AIF in wild-type (30.1 vs. 87.2% in
controls) and Apaf1-deficient neuron cultures (35.2 vs.
92.2% in controls), but did not induce a significant decrease
in p53-deficient cultures (88.3 vs. 91.5% in controls) (Fig. 3
C). This indicated that camptothecin triggered the release of
AIF from mitochondria by a p53-dependent, but Apaf1-
independent, mechanism.
We then assessed whether AIF release was associated with
other mitochondrial events involved in DNA damage–
induced neuronal cell death, such as mitochondrial depolar-
ization and cytochrome-c release (Stefanis et al., 1999).
Neurons treated with camptothecin were monitored for the
mitochondrial release of cytochrome-c or AIF by immuno-
fluorescence staining. In parallel cultures, mitochondrial de-
polarization was assessed in live cells by CMX-Ros labeling.
This fluorescent dye is selectively incorporated into mito-
chondria with an intact transmembrane potential and there-
fore serves as an indicator of mitochondrial depolarization.
Our results demonstrate that camptothecin induced a time-
dependent decrease in the fraction of cells retaining mito-
chondrial transmembrane potential as well as mitochondrial
cytochrome-c and AIF (Fig. 4 A). Interestingly, release of cy-
tochrome-c appeared to precede the loss of AIF and mito-
chondrial membrane potential such that within 12 h of
camptothecin treatment, there was already a significant de-
crease in the fraction of cells maintaining mitochondrial cy-
tochrome-c staining (
 
 
 
45%), but only a modest decrease in
the fraction of cells exhibiting mitochondrial AIF (
 
 
 
5%)
and CMX-Ros (
 
 
 
15%) staining (Fig. 4, A and B). These re-
sults suggest that AIF and cytochrome-c release occur by dif-
ferent mechanisms during p53-induced neuronal cell death.
 
Mitochondrial release of AIF and caspase-independent 
cell death are regulated by Bax and Bcl-2
 
The Bcl-2 gene family consists of proapoptotic and antiapop-
totic members that are thought to regulate cell death through
their opposing effects on mitochondrial-mediated death pro-
cesses (Adams and Cory, 1998; Gross et al., 1999). We and
others have previously shown that the proapoptotic member
Bax plays a critical role in regulating p53-induced cyto-
chrome-c release, caspase activation, and neuronal cell death
Figure 5. Bax mediates mitochondrial depolarization and the 
release of AIF during camptothecin-induced neuronal cell death. 
Wild-type and Bax-deficient neurons were treated with camptothecin 
and after 24 h, cells were either labeled with CMX-Ros to assess 
mitochondrial transmembrane potential or fixed and immunostained 
for AIF. Representative images were taken, and the proportion of 
cells exhibiting positive mitochondrial staining for CMX-Ros (A) or 
AIF (B) was scored (n   3).
Figure 6. Bcl-2 inhibits camptothecin-induced AIF release and 
caspase-independent cell death. (A) Western blot analysis of Bcl-2 
expression in cortical neurons 48 h after infection with Ad-Bcl-2 or 
the control vector Ad-LacZ at 50 MOI. (B) Wild-type and Apaf1-
deficient cortical neurons were infected with Ad-Bcl-2 or Ad-LacZ 
for 48 h before treatment with camptothecin (10  M) or vehicle 
control, and neuronal survival was determined at the indicated 
times by live/dead assay (n   3). (C) Cortical neurons were infected 
with Ad-Bcl-2 or Ad-LacZ for 48 h and then treated with camptothecin 
or vehicle control for an additional 48 h. Cells were then labeled 
with CMX-Ros to assess mitochondrial transmembrane potential, or 
fixed and immunostained for AIF or cytochrome-c. Representative 
images were captured, and the fraction of cells maintaining mito-
chondrial membrane potential or mitochondrial cytochrome-c/AIF 
staining was scored (n   3). 
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(Xiang et al., 1998; Cregan et al., 1999; Keramaris et al.,
2000; Morris et al., 2001). Here we investigated the role of
Bax and Bcl-2 in the regulation of p53-induced mitochon-
drial events and caspase-independent cell death. To deter-
mine whether Bax was required for these mitochondrial
death processes, Bax
 
 
 
/
 
 
 
 and Bax
 
 
 
/
 
 
 
 neurons were treated
with camptothecin and then examined for the loss of mito-
chondrial membrane potential (Fig. 5 A) and AIF release
(Fig. 5 B). Camptothecin triggered mitochondrial depolariza-
tion and the release of AIF in a significant fraction of Bax
 
 
 
/
 
 
 
neurons (
 
 
 
60 and 
 
 
 
50% respectively), but not in Bax-defi-
cient neurons, suggesting that Bax mediates p53-induced mi-
tochondrial depolarization and AIF release in neurons.
We then asked whether the antiapoptotic member,
Bcl-2, could block these cell death processes. Apaf1
 
 
 
/
 
 
 
 and
Apaf1
 
 
 
/
 
 
 
 neurons were infected with a recombinant ade-
noviral vector expressing either Bcl-2 or the control gene
LacZ and then treated with camptothecin. In wild-type
cells, where neuronal death occurs via a caspase-mediated
process, the extent of cell death at 24 h after camptothecin
treatment was significantly reduced in neurons infected
with Ad-Bcl-2 (75.7% survival), as compared with the
control vector Ad-LacZ (20.6% survival) (Fig. 6 B). Over-
expression of Bcl-2 in Apaf1
 
 
 
/
 
 
 
 neurons, where neuronal
cell death occurs via a slower caspase-independent mecha-
nism, also resulted in a significant increase in neuronal sur-
vival 72 h after camptothecin treatment relative to control
(71.2 vs. 17.5% in Ad-LacZ controls). Furthermore, en-
forced expression of Bcl-2 resulted in a marked increase in
the fraction of camptothecin-treated neurons maintaining
mitochondrial transmembrane potential (58.0 vs. 11.9%),
and positive mitochondrial staining for cytochrome-c
(68.9 vs. 8.7%) and AIF (62.3 vs. 15.8%) relative to camp-
tothecin-treated controls (Fig. 6 C). Taken together, these
results demonstrate that Bax and Bcl-2 regulate both the
p53-induced release of cytochrome-c and AIF from mito-
chondria as well as the caspase-dependent and -indepen-
dent cell death pathways.
Figure 7. AIF can induce neuronal cell death independent of 
Apaf1 and caspase activation. Apaf1-deficient neurons were 
infected at 75 MOI with Ad-AIF or the control vector Ad-LacZ and 
cultured in the presence or absence of BAF (50  M). (A) Neuronal 
survival was determined at the indicated times by MTT assay (n   4). 
(B) Photomicrographs of TUNEL staining and nuclear morphology 
in neurons 72 h after infection with Ad-LacZ or Ad-AIF. Bar, 20  m. 
(C) The proportion of apoptotic cells was measured at 72 h by 
TUNEL staining (n   3).
Figure 8. AIF induces neuronal cell death independent of Bax. 
(A) Wild-type and Bax-deficient neurons were infected with Ad-AIF 
or Ad-LacZ at increasing MOI, and cell survival was determined at 
72 h by MTT assay (n   3). (B) Neurons were infected with Ad-LacZ 
or Ad-AIF at 75 MOI and cells were fixed and stained for cyto-
chrome-c and counterstained with Hoechst. Bar, 15  m. 
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AIF can induce Apaf1/caspase-independent 
neuronal cell death
 
To determine whether AIF is capable of inducing caspase-
independent neuronal cell death, we infected Apaf1
 
 
 
/
 
 
 
 neu-
rons with a recombinant adenoviral vector expressing AIF or
LacZ as a control. AIF overexpression caused a marked reduc-
tion in neuronal survival relative to Ad-LacZ–infected controls
and by 72 h, 
 
 
 
35% of Ad-AIF–infected neurons remained
viable (Fig. 7 A). Neurons undergoing AIF-induced cell death
exhibited morphological features similar to that observed in
p53-induced caspase-independent cell death, including inter-
mediate nuclear pyknosis and partial chromatin condensation
(Fig. 7 B, inset). In addition, Ad-AIF induced a significant in-
crease in the fraction of TUNEL-positive neurons (46.6%)
relative to Ad-LacZ–infected controls (10.1%) (Fig. 7, B and
C). Interestingly, this DNA fragmentation was not associated
with caspase-3 activation (unpublished data) and the fraction
of TUNEL-positive cells was not significantly decreased in
the presence of BAF (46.6 vs. 41.6%; Fig. 7 C). This indi-
cated that AIF can trigger DNA fragmentation and neuronal
cell death independent of caspase activation.
We then asked whether cell death induced by AIF was de-
pendent on Bax. Ad-AIF induced a similar dose-dependent
increase in cell death in Bax
 
 
 
/
 
 
 
 and Bax
 
 
 
/
 
 
 
 neurons (Fig. 8
A). This suggests that AIF can induce cell death indepen-
dently of Bax, which is consistent with the idea that AIF
functions downstream of Bax in neuronal cell death. Inter-
estingly, many (
 
 
 
45%) Ad-AIF–infected cells exhibiting ap-
optotic nuclear morphology had maintained mitochondrial
cytochrome-c staining (Fig. 8 B).
 
Apaf1/caspase-independent neuronal cell death is 
blocked by AIF neutralizing antibodies
 
Finally, to determine whether AIF function is necessary for
p53-mediated cell death, we microinjected Apaf1
 
 
 
/
 
  and
Apaf1
 /  neurons with an AIF-specific neutralizing antise-
rum (Susin et al., 1999) and assessed cell death after camp-
tothecin treatment. In Apaf1
 /  neuronal cultures, the
extent of camptothecin-induced cell death was not signifi-
cantly different in cells microinjected with AIF antiserum, as
compared with cells injected with preimmune serum (72.7
vs. 77.3%; Fig. 9 A). This indicated that AIF is not required
for the caspase-dependent pathway of p53-mediated cell
death. In contrast, microinjection of AIF antisera into
Apaf1
 /  neurons resulted in a significant decrease in camp-
tothecin-induced cell death relative to control (34.7 vs.
53.8%; P   0.01), suggesting that AIF plays a functional
role in the caspase-independent pathway of neuronal cell
death (Fig. 9 B). AIF immunostaining was performed to de-
termine whether microinjection of AIF antisera prevented
camptothecin-induced AIF translocation. As depicted in
Fig. 9 C, whereas 67.3   11.8% of Apaf1
 /  neurons in-
jected with preimmune serum exhibited positive nuclear
staining for AIF, only 16.7   4.9% of neurons injected with
AIF antisera displayed distinct nuclear translocation after
camptothecin treatment. These results indicated that the
microinjected AIF antisera substantially diminished the abil-
ity of AIF to target the nucleus.
In summary, our results demonstrate that in addition to
a caspase-mediated process activated by Apaf1, p53 can
also induce cell death in Apaf1-deficient neurons via a cas-
pase-independent mechanism. Furthermore, we have
shown that AIF is an important determinant in the cas-
pase-independent pathway and functions downstream of
Bax in neuronal cell death.
Discussion
Caspases have been recognized as important mediators of
apoptotic cell death after acute neuronal injury (Eldadah
Figure 9. Camptothecin-induced caspase-
independent cell death and AIF translocation is 
inhibited by AIF neutralizing antibodies. (A) Wild-
type or (B) Apaf1-deficient neurons were microin-
jected with either AIF antiserum or preimmune 
serum along with a fluorescent marker (Alexa
®488-
dextran) and then treated with camptothecin. After 
36 h, cells were fixed, stained with Hoechst, and 
the fraction of Alexa
®-positive cells exhibiting 
nuclear pyknosis was scored (n   3). (*, P   0.01, 
ANOVA). (C) AIF immunostaining in Apaf1
 /  
neurons microinjected with preimmune serum 
or AIF antisera and treated with camptothecin. 
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and Faden, 2000). However, caspase inhibition has typically
resulted in limited or transient neuronal protection (Rideout
and Stefanis, 2001). This lack of therapeutic efficacy has
been attributed to the persistence of additional or compensa-
tory pathways of neuronal cell death. Despite the growing
recognition that caspase-independent cell death plays a sig-
nificant role in neuronal injury, the molecular mechanisms
regulating this cell death remain poorly defined.
P53 has been recognized as a key regulator of cell death af-
ter neuronal injury (Morrison and Kinoshita, 2000). In this
paper, we have demonstrated that p53 triggers neuronal cell
death via a caspase-mediated process in the presence of
Apaf1, and via a caspase-independent process in the absence
of Apaf1. More importantly, we provide several lines of evi-
dence supporting a role for AIF in the regulation of caspase-
independent cell death triggered by neuronal injury. We
have demonstrated that (a) AIF redistributes from the mito-
chondria to the nucleus after p53-mediated neuronal injury,
that (b) enforced expression of AIF can induce neuronal cell
death in the absence of caspase activity with morphological
features characteristic of caspase-independent cell death, and
that (c) microinjection of neutralizing antibodies against
AIF significantly decreases caspase-independent cell death
induced by DNA damage. It was noted, however, that mi-
croinjected AIF antisera was moderately more effective at
preventing AIF translocation (at least as detectable by im-
munostaining) than neuronal cell death. It is unclear
whether this is due to incomplete inhibition of AIF translo-
cation or rather to the possible involvement of other media-
tors of caspase-independent cell death. Indeed, the mito-
chondrial-derived proteins endonucleaseG and HtrA2 have
recently been identified as potential caspase-independent
mediators of cell death (Li et al., 2001; Suzuki et al., 2001;
van Loo et al., 2001). Unfortunately, more definitive studies
on the role of AIF in neuronal injury have been precluded by
the lack of an AIF-null mouse model. Interestingly, AIF ap-
pears to be essential for the programmed cell death that oc-
curs during cavitation of embryoid bodies (Joza et al., 2001).
Attempts to generate chimeric mice from AIF-deficient ES
cells have likely failed as a result of this defect in the early
stages of embryogenesis (Joza et al., 2001). Thus, future
studies of AIF function in neuronal injury in vivo will rely
on the development of a conditional or tissue-specific
knockout mouse model.
Two distinct stages of nuclear apoptosis have been identi-
fied during the apoptotic process (Daugas et al., 2000; Susin
et al., 2000). In stage I, nuclei exhibit a wrinkled pattern of
peripheral chromatin condensation, which is typically asso-
ciated with high molecular weight DNA fragmentation
( 50 kb). As cell death progresses, nuclei adopt a stage II
morphology, which is characterized by marked chromatin
condensation and the formation of nuclear bodies. Further-
more, it has been shown that nuclear apoptosis is restricted
to a stage I morphology when caspases are inhibited (Daugas
et al., 2000; Susin et al., 2000). When recombinant AIF is
added to isolated nuclei or injected into mouse embryo fi-
broblasts, nuclei adopt a stage I–type apoptotic morphology
and exhibit high molecular weight DNA fragmentation,
both of which occur independently of caspase activation
(Susin et al., 1999, 2000; Daugas et al., 2000). In contrast,
injection of active caspase-3 or caspase-activated DNase
(CAD/DFF) caused a stage II–type nuclear morphology and
resulted in the cleavage of DNA into oligonucleosomal frag-
ments (Susin et al., 2000). In this paper, we have shown that
in wild-type neurons, p53 initiates a caspase-mediated cell
death process that manifests in a stage II–type nuclear apop-
totic morphology. In contrast, p53-mediated cell death pro-
cesses in Apaf1-deficient neurons resulted in a stage I–like
apoptotic nuclear morphology, consistent with a caspase-
independent apoptotic mechanism. Interestingly, wild-type
neurons undergoing p53-mediated cell death in the presence
of a caspase inhibitor also exhibited stage I apoptotic nuclei.
Furthermore, we have shown that enforced expression of
AIF induces stage I apoptotic morphology and DNA frag-
mentation in neurons in a caspase-independent manner.
The Bcl-2 protein family consists of proapoptotic and an-
tiapoptotic members that are thought to regulate cell death
through their opposing effects on mitochondrial-mediated
death processes (Adams and Cory, 1998; Gross et al., 1999).
Accordingly, the proapoptotic member Bax has been re-
ported to translocate from the cytoplasm to the mitochon-
dria in response to certain death signals (Goping et al.,
1998), where it causes permeabilization of the mitochon-
drial membrane and the release of apoptogenic factors like
cytochrome-c (Finucane et al., 1999). Upon release into the
cytosol, cytochrome-c forms a complex with dATP and
Apaf1, which then recruits and activates caspase-9 and ini-
tiates the caspase cascade. We and others have shown that
Bax deficiency provides long-term protection against p53-
induced cell death, suggesting that Bax is required for both
caspase-dependent and -independent modes of neuronal cell
death (Xiang et al., 1998; Cregan et al., 1999). Similarly, we
report here that Bcl-2 can block both Apaf1/caspase-depen-
dent and -independent neuronal death pathways induced
by p53. We have previously demonstrated that Bax is re-
quired for p53-induced cytochrome-c release (Keramaris et
al., 2000) and caspase activation in postmitotic neurons
(Cregan et al., 1999). The results presented here indicate
that Bax is also required for p53-induced mitochondrial de-
polarization and the release of AIF. Interestingly, our studies
on the relative kinetics of p53-induced mitochondrial events
indicated that cytochrome-c release preceded the release of
AIF, at least in the absence of caspase activation. Further-
more, similar to a previous report (Stefanis et al., 1999), our
results suggest that cytochrome-c is released before the col-
lapse of mitochondrial membrane potential. In contrast, the
release of AIF appears to occur after, and possibly as a conse-
quence of, mitochondrial depolarization during p53-medi-
ated cell death. It has previously been reported that AIF can
be released from the mitochondria simultaneously with, or
even before, cytochrome-c during staurosporine-induced
cell death of Rat-1 fibroblasts (Daugas et al., 2000; Loeffler
et al., 2001). One may hypothesize that the sequence of
these events may depend upon the nature of the processes
leading to mitochondrial permeabilization. Because we have
shown that Bax is required for the release of both cyto-
chrome-c and AIF, the different kinetics of their release sug-
gests that Bax mediates the release of these factors through
either distinct mechanisms or the progressive action of a
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The precise mechanism by which Bax mediates mitochon-
drial membrane permeabilization and the release of apopto-
genic factors remains highly controversial. However, two
main hypothetical models have been proposed. In the first,
Bax is proposed to oligomerize upon insertion into the mito-
chondria and to directly form pores within the outer mem-
brane. This hypothesis is supported by the finding that Bcl-2
family proteins share some structural homology with the
transmembrane domain of diptheria toxin and the colicins,
and that Bcl-2 family proteins can form pores in artificial
membranes (Muchmore et al., 1996; Antonsson et al., 2000;
Saito et al., 2000). In the other model, Bax is proposed to
interact with existing membrane channels and to modulate
their conductivity. Accordingly, Bax has been reported to in-
teract with the voltage-dependent anion channel and studies
in yeast cells and isolated mitochondria have suggested that
this interaction is required for Bax-mediated mitochondrial
effects (Shimizu et al., 1999, 2000). On the other hand,
other research groups have indicated that the inner mito-
chondrial membrane protein, adenine nucleotide transloca-
tor (ANT), is the critical Bax target (Marzo et al., 1998). It
is possible that more than one of these models is correct and
Bax can form different types of channels. In this case, it is
conceivable that the different apoptogenic factors could be
released through distinct channels. Alternatively, Bax could
alter membrane permeability either by forming pores itself
or by modulating existing channels, allowing the selective re-
lease of smaller molecules like cytochrome-c. This increase
in membrane permeability could lead to swelling of the mi-
tochondrial matrix and eventual lysis of the outer mitochon-
drial membrane (Vander Heiden et al., 1997), resulting in
the release of larger apoptogenic molecules like AIF.
In summary, we have shown that p53 induces neuronal
cell death through a caspase-mediated process in the pres-
ence of Apaf1, and through a caspase-independent process
in the absence of Apaf1. Furthermore, we have shown that
AIF is an important regulator of the caspase-independent
cell death pathway and functions downstream of Bax. The
fact that blocking AIF function with neutralizing antibodies
provides significant protection against cell death suggests
that AIF may represent an important therapeutic target for
neuroprotection after acute injury.
Materials and methods
Mice and primary neuronal cultures
P53, Bax (Jackson ImmunoResearch Laboratories), and Apaf1 (Cecconi et
al., 1998) mice were maintained on a C57BL6 background to maintain ge-
netic uniformity. Genotyping for Bax (Cregan et al., 1999), p53, and Apaf1
(Fortin et al., 2001) was done by PCR as previously described. Cortical
neurons were cultured from dissociated cortices of E14.5 mice as previ-
ously described (Fortin et al., 2001).
Recombinant adenovirus infection
Total RNA was extracted from postnatal day eight mouse cortices using Tri-
zol reagent (Invitrogen). 1  g of total RNA was used for first strand cDNA
synthesis and targeted gene amplification using Superscript One-Step RT-
PCR kit (Invitrogen). cDNA synthesis was performed at 50 C for 45 min
followed by a 2-min initial denaturation step at 94 C. This was followed by
37 cycles at 94 C for 30 s, 60 C for 30 s, and 72 C for 2 min using mouse-
specific AIF primers: AIF forward (CCCGGGATGTTCCGGTGTGGAGG)
and AIF reverse (CCCGGGTCAATCTTCATGAATG) containing Xma1 re-
striction sites. The resulting product was sequenced and confirmed to be
AIF. Recombinant adenoviral vectors carrying human p53, Bcl-2, AIF, or
LacZ expression cassettes were constructed, purified, and titered as previ-
ously described (Cregan et al., 2000). Recombinant adenoviral vectors
were added to cell suspensions immediately before plating.
Cell viability assays
Neurons were infected with adenovirus at the time of plating or treated
with camptothecin with or without BAF (Enzyme System Products) after 2 d
in culture. Cell survival was measured by three different methods: live/
dead staining, MTT assay (Cell Proliferation Kit; Promega), or TUNEL. At
the times indicated, neuronal viability was determined using the Live/Dead
Cytotoxicity Kit (Molecular Probes Inc.) according to the manufacturer’s
instructions. Representative samples were photographed using ZEISS Axio-
vert 100 with a Northern Eclipse Sony Power HAD 3CCD color video
camera. Survival was determined as the fraction of total cells exhibiting
positive staining for calcein-AM. TUNEL labeling was used to visualize
cells with fragmented DNA. At the indicated times, cells were fixed in 4%
paraformaldehyde for 20 min, washed in three changes of PBS, and then
labeled by TUNEL, as previously described (Cregan et al., 1999), and
counterstained with Hoechst 33258 (1  g/ l) for 5 min. The fraction of
TUNEL-positive cells as a percentage of total cell number was determined.
For both live/dead and TUNEL assays, a minimum of 500 cells was scored
for each treatment and the data represent the mean and standard deviation
from three independent experiments. In certain experiments, survival was
measured by colorimetric MTT assay as previously described (Cregan et
al., 1999).
Antibodies, immunofluorescence staining, and cell counts
The rabbit antiserum for AIF was produced by immunizing rabbits with a
mixture of synthetic peptides (coupled to keyhole limpet hemocyanin) cor-
responding to amino acid residues 151–170 and 181–200. The polyclonal
antibody was purified through peptide-conjugated affinity chromatography
and was found to specifically recognize both forms of AIF (67 and 57 kD),
but predominately recognized the 57-kD truncated form of AIF. No other
immunoreactive bands were detected with the AIF antibody. The specifici-
ties of anti-AIF antiserum and purified antibody were confirmed by the ab-
sence of 57- and 67-kD bands after preadsorption with peptides corre-
sponding to amino acid residues 151–170 and 181–200 of AIF
(unpublished data). Cytochrome-c and AIF immunostaining was performed
as previously described (Keramaris et al., 2000). Representative fields were
photographed and images were captured using a ZEISS Axioskop-II or Ax-
iovert 100 microscope equipped with a Northern Eclipse Sony power
HAD 3CCD color video camera. The fraction of cytochrome-c– or AIF-
positive cells was determined as the proportion of total cells exhibiting a
punctate cytoplasmic staining pattern. A minimum of 400 cells was scored
per treatment and data represent the mean and standard deviation from
three independent experiments.
Mitochondrial membrane potential
Loss of mitochondrial membrane potential was monitored in unfixed cells
using the membrane potential–dependent dye Mitotracker CMX-Ros (Mo-
lecular Probes Inc.). This fluorescent dye is selectively incorporated into
mitochondria with an intact transmembrane potential and therefore serves
as an indicator of mitochondrial depolarization. Cells were incubated with
CMX-Ros at 0.25  M for 30 min at 37 C, washed in fresh media, and im-
ages were captured as described above. The fraction of cells maintaining
mitochondrial transmembrane potential was determined by counting
CMX-Ros–positive cells relative to total cell number in corresponding
phase images. A minimum of 400 cells was scored per treatment and data
represent the mean and standard deviation from three independent experi-
ments.
Western blot analysis
Cells were lysed in RIPA buffer for 20 min on ice and the soluble extract
was recovered by centrifugation. Extracts containing 30  g of protein were
separated on a 10% acrylamide gel and transferred to a nitrocellulose
membrane. Membranes were blocked for 2 h in 5% skim milk and then in-
cubated for 1 h with monoclonal antibodies directed against Bcl-2 (BD
Transduction Labs)/cytochrome-c (BD Biosciences), or polyclonal antibod-
ies to AIF (Dawson) and actin (Santa Cruz Biotechnology, Inc.) for stan-
dardization. Membranes were washed in TPBS (25 mM Na2HPO4, 5 mM
NaH2PO4, 0.9% NaCl, 0.1% Tween-20) and then incubated for 1 h with
appropriate secondary antibodies. Membranes were again washed and
then developed by an enhanced chemiluminescence system according to
the manufacturer’s instructions (PerkinElmer).516 The Journal of Cell Biology | Volume 158, Number 3, 2002
Caspase activity assay
Cells were harvested and extracted for 15 min on ice in caspase lysis
buffer, and 10  g of protein was used for caspase activity assay as previ-
ously described (Cregan et al., 1999). Caspase activity is reported as the ra-
tio of fluorescence output in treated samples relative to corresponding un-
treated controls.
Microinjection and cell death quantitation
Microinjection solution containing 3 mg/ml Alexa
®488-dextran (Molecular
Probes Inc.) and either AIF antiserum (Susin et al., 1999) or preimmune
rabbit serum diluted in PBS was injected at 150 hPa (0.5 s) into neurons in
35-mm dishes using Femtotip needles (Eppendorf Inc.). Neurons were then
treated with camptothecin (or vehicle control) and after 36 h, cells were
fixed in 4% paraformaldehyde, washed in PBS, and stained with Hoechst
33258 (1  g/ml). The extent of cell death was determined as the fraction of
Alexa
®488–positive cells exhibiting pyknotic nuclei. Where indicated, the
cells were immunostained for AIF and the fraction of microinjection-posi-
tive cells exhibiting nuclear AIF staining was determined. A minimum of
200 cells were scored per treatment and data represent the mean and stan-
dard deviation from three independent experiments.
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